Anixa Biosciences, Inc. (ANIX)

Anixa Biosciences Income Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021
Revenue	-	-	0.21	-	0.51
Cost of Revenue	-	-	0.16	-	0.39
Gross Profit	-	-	0.05	-	0.13
Selling, General & Admin	6.63	7.44	6.29	7.17	7.07
Research & Development	5.07	6.4	4.77	6.7	6.19
Operating Expenses	11.7	13.83	11.06	13.88	13.26
Operating Income	-11.7	-13.83	-11.01	-13.88	-13.14
Interest & Investment Income	0.67	1.13	1.08	0.1	0
EBT Excluding Unusual Items	-11.03	-12.7	-9.93	-13.77	-13.13
Gain (Loss) on Sale of Assets	-	-	-	-	0.01
Pretax Income	-11.03	-12.7	-9.93	-13.77	-13.13
Earnings From Continuing Operations	-11.03	-12.7	-9.93	-13.77	-13.13
Minority Interest in Earnings	0.1	0.14	0.12	0.18	0.17
Net Income	-10.93	-12.55	-9.81	-13.6	-12.95
Net Income to Common	-10.93	-12.55	-9.81	-13.6	-12.95
Shares Outstanding (Basic)	32	32	31	30	29
Shares Outstanding (Diluted)	32	32	31	30	29
Shares Change (YoY)	1.74%	2.96%	1.99%	6.28%	28.57%
EPS (Basic)	-0.34	-0.39	-0.32	-0.45	-0.45
EPS (Diluted)	-0.34	-0.39	-0.32	-0.45	-0.45
Free Cash Flow	-7.17	-7.34	-6.21	-6.49	-4.94
Free Cash Flow Per Share	-0.22	-0.23	-0.20	-0.21	-0.17
Gross Margin	-	-	23.33%	-	24.80%
Operating Margin	-	-	-5243.33%	-	-2565.63%
Profit Margin	-	-	-4671.91%	-	-2530.08%
Free Cash Flow Margin	-	-	-2956.67%	-	-964.45%
EBITDA	-	-	-	-	-13.1
D&A For EBITDA	-	-	-	-	0.04
EBIT	-11.7	-13.83	-11.01	-13.88	-13.14

Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q